🇺🇸 FDA
Patent

US 11890272

Non-sedating dexmedetomidine treatment regimens

granted A61KA61K31/4174A61K47/10

Quick answer

US patent 11890272 (Non-sedating dexmedetomidine treatment regimens) held by BioXcel Therapeutics, Inc. expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioXcel Therapeutics, Inc.
Grant date
Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/4174, A61K47/10, A61K47/26, A61K47/34